FLT3 and differentiated thyroid carcinoma: Sorafenib is another multitarget FLT3 inhibitor, FDA-approved for the treatment of non-hematological malignancies such as hepatocellular, renal cell, and differentiated thyroid cancers [75] and whose efficacy has been very recently shown in prevention of disease relapse after allo-HSCT in patients with FLT3-ITD AML [76].